Member Info for sadoldgit

RNS stating 3,000,000 shares issued.

Most of these already gold l would suggest.

No more 3 million shares to be issued after this current issue.

Very predictable RNS,

Nicely, seemed very concerned for us all about the impending issuance of new shares.

According to one of his posts, he needs 5 pounds to break even, poor sod.

That MAJWandCo thankyou for posting. Have tripled my holding here and took advantage of the WRAP offer.

You knew and know nothing of the science here as you have demonstrated.

Is it just coincidence that MAJW the first and last letters of the CLO a Mr Mark Wheeler are the same.

You get to see him on the golf course along with James Rooke? They both love golf with even the Riverfort CLO commentating on the reduction of his golf handicap.

Maybe you were on the golf course this morning,

All done very nicely.

Regards

Nicely you are spot on with your first part.

Nicely, when is the news due then?

Nicely, IT CAME DOWN IN A STRAIGHT LINE FROM 105P OR HAD YOU NOT NOTICED?

I will go for 51p.

Based on where we sit financially with no reliance on RF and a million and half plus in the coffers.

News due soon on SDC1801 phase1 data.

Update on CCT245737 due anytime.

Regards

Good morning cupacoffee.

Suggest you look at RNS,s

Sareum experienced a problem with MHRA approval for SDC1801, now Sareum had tested in preclinical with 30 x treatment dose with no adverse effects.

MHRA requested more clarification, but exactly what this is we do not know.

Cut a long story short it has subsequently entered phase 1 clinical trial in the land of down under.

A further setback was Sierra Oncology returned the license for 737 back to the CPF at end of 22.

No reason given but l do have my views on this.

Subsequently SRA737 has now been on licensed to a US private pharma of which the details are not disclosed. I believe the signing of the contract is still yet to take place.

Most difficult set back was Riverfort Global finance equity release deal.

The price of Sar dropped from around 300p per share and with set backs by MHRA and delay, the return of 737 the SP suffered taking to around 105p.

Deal with Riverfort in August 23 caused a rapid decline of SP due to the finance described as a death spiral.

In effect rather than pay back loan in cash they take shares at a discounted price plus fees and options on top.

The more the share fall the more shares that have to he issued and the process continues until nothing is left.

Look at Riverfort finance and how companies have been devastated!

Sareum due to the terms contained within the contract could not draw down a further 300k

Share holders many of which are here raised under the WRAP offer 1.2 million pounds of which initially were capped at 300k pounds.

As a result Sareum now have sufficient funding to complete and evaluate phase 1a safety data in SDC1801.

A matter of a 2 to 3 hundred thousand pounds remains owing to Riverfort. We the rising shareprice shares will be issued to RF as they request. They have been off loading shares at a rapid rate.

The result the RF finance no longer has a stranglehold on the SP and the price has risen from a low of 10p.

To achieve the appropriate value Sareum had prior to Riverfort and the number of additional.shares issued you are looking at circa 70p per share which should be easily achievable.

News of the WRAP funding and non reliance on RF death spiral finance has removed the devastating downward pressure of Sareum.SP

Regards

There certainly are Carter19.

They take great delight reading here but unfortunately they cannot understand or refuse to understand anything that goes against their own spiteful, hate filled, agenda.

I don't mind rattling their cage now and again even if the lights are on but no one at home.

Steady rises should be achieved tomorrow and next week with a substantial rise on positive RNS.

Regards

Good evening MegRS300,

Yes a pound a share is easily achievable and we are climbing towards that as the realisation of the Riverfort Finance deal is losing its stranglehold.

Indeed, we are further forward in development of 1801 too

Riverfort will be gone soon, very soon!

A fund raise l believe will come soon, phase 2a trial which will lead into phase 2b.

At this stage the value of SDC will rise appreciably as you well know.

It is indeed a competitive market but pretty certain we will have nailed Psoriasis, precisiin biomarker data will give Indication as to suitability in other indication.

Long and good patent protection an added bonus.

Regards

Paragraph relates to the gruesome twosome over on ADVN,

Apologies for any confusion caused here.

8.2 million shares traded today.

Can safely say good bye to the 20's tomorrow, for good.

On a positive RNS you can kiss the 30's goodbye also.

Dosaging been carried out within the therapeutic area which l believe exceeded Sareums expectations with regards to uptake.

Satisfying to think of the contribution made by the capsule as a method of oral intake.

Albeit a little while away, phase 2a to phase 2b transition should place the value of SDC1801 in the 400 to 800 million arena.

The safety profile of Tyk2 with the added bonus of an optimum.amount of Jak1 to increase efficacy.

Regards to all LTH's here.

No need to rattle the cage here either, for the blind that have a tendency to be negative of Sareums future, sitting in a chair rocking backwards and forwards in a trance like state whilst nursing a can of like warm special brew half inched from their local store.

To them, get a life.

Blastoid, Riverfort are out of the equation.

We will not be drawing down any more funding from them.

They will request a further tranche of shares.

May well be done in either 1 or 2 tranches l feel.

The longer they RF leave it the less shares they will require due to increase in SP.

RNS I would expect Monday morning,

Riverfort will be gone by end of month!

No more cheap shares flooding the market.

Somebody somewhere is responsible for this catastrophe and my view is that it is Peel Hunt.

Somebody advised that this was the best deal.

Come hell or high water l will be attending the AGM and questions need to be answered.

Yes the SP will climb from what at present is peanuts.

Regards

Good afternoon Rebster408.

I did sell just under a million at 9.2 p old money.

Not sure where MAJWandCo, Puma or Robin Hood of AIM are these days, very quiet.

Still along way to climb on this one just to get back to normality or around 70p per share to bring market cap to as it was pre Right Fleecerd equity swap.

That will be gone very very soon within next week or so, shares will become far less a binding then we can expect steady rise up until the good news.

1 Riverfory bombed out

2 clinical trial safety data being satisfactory and progression to either phase1b or 2a.

3 possibly progress with details of on licensee for 737 along with their progress and intent.

Just dediating a tad here but l see a similarity between Mark Wheelet CLO of Riverfort and MAJWandCo as well as James Rooke and Puma.

Maybe just coincidence but interesting posts on LinkedIn thst reflect certain content of posts they put here. Nothing like a good game of golf to spread the word on the street haha.

Needs investigating as far as l am concerned.

Onwards and upwards and with 8 months if constant decline in the SP due to Rivetfort finance it is now time for share price reversal and we are still a very long way from where we should be.

You can have a good laugh over at the ADVN chatboatd at the absolute bile that they post.it is about time that two of them were put back in their specimen bottles in the lab.

How can you claim have achieved nothing in 20 years and at the same time claim to have sold at the spike in 2021.

Why on Earth don't the come on here and try and achieve reasoned debate?

Banned from here for the same behaviour they now carry out over at ADVN

Regards to all

Interesting link below. One of the Indications in SDC1801 patent description is Alzheimers

https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.12445#:~:text=The%20use%20of%20baricitinib%20in,CNS%20and%20may%20suppress%20neuroinflammation.

Regards

Shouldn't have a problem buying.

Riverfort can forward sell. They don't have many left l might add.

Sp will still rise steadily as market cap still low.

Regards

I am not misleading! I have level 2 as well.

What is your problem?

Looks like RF unloading a few now.

All will be fine.

Regards

Don't go mad Wiggly keep a degree of calmness.

You can go on the ADVN chat site.

You will get a completely different opinion from a couple of posters on their.

So you can at least see what they see as downsides and make your own conclusions as to what is and what is not a viable investment.

Feel free to ask here, as there are knowledgeable posters that have been here for a significant period of time.

Regards

May get a slight drop as 3 million additional shares issued to Riverfort finance. It may well be they have forward sold most of them.

Regards

There is absolutely no reason as to why the SP should not recover Wiggly.

I did say a few days ago that an individual here who had an average of 61p should be in profit by end of May,

I also put that in my 100% belief on the removal of finance contract the SP should have a clear runway up to 100p

Further along we await news of phase1a clinical trial.

Following this with sufficient funding we can go phase 1b or phase 2a.

Advantage of phase 2 trials is therapeutic doses can be established per indication ( that cannot happen in phase 1b). Disadvantages are increased cost due to the number of clinical trial volunteers we get. Typically 100 to 300. Before anybody pipes up about Sareum only using 25 patients , they need understand that at these low numbers it is nothing more than proof of concept. However, phase 2 can start in 2a and lead into phase2b without further phase application.

Plus side is on satisfactory progression it greatly increases the value of SDC1801 and hence bring greater value to its shareholders, which will take some doing after the virtual abortion of a finance deal which had wiped around 90% from an already down trodden price.

Choice is yours what you do and when you tend to exit. As l see it steady growth whilst terminating RF finance deal followed by satisfactory phase 1a safety data results.

In addition we do have SRA 737 formerly CCT245737 a checkpoint 1 kinase inhibitor which was on licensed to a non named private company in the US.

That is about as much as l can say.

As for advice your two biggest enemies will be fear and greed. Fear of missing out that is.

Don't forget to take profit, when to take out is just as important if not more so than when to put in.

Regards

Funnyguy you are an extremely erratic

You post:-

'RE: Interesting Parallels 17 Apr 2024 02:27

Considering the current SAR performance, you would be bonkers not to take a price of 200-300m. I have little confidence that the results will propel this into the billions, its track record has been woeful and every turn it has disappointed. However, its not unrealistic with a bit of market spin this could get to a pound in a short time. To me sar is now definitely a short term play.'

What results are we looking at here?

Data results on its own will not reach 200 to 300 million, l will agree.

Phase 2a leading to phase 2b very likely to exceed the 300 million.

In addition we have SDC1802 for oncology coming to the end of preclinical.

Would you care to put your expert opinion as to a value of here?

Early Jak inhibitors all have black NDA black box warnings to adverse side effects.

No early first generation Jak 1, 2 and 3 inhibitors do not have the dreaded black box warnings either irrespective of claimed selectivity over.

Along comes Deucravacitinib, an allosteric Tyk2 inhibitor that has very good acceptable safety profile. It has proved mediocre to good efficacy in Psoriasis. It failed to meet its end points in ulcerative colitus. Very little different to the placebo used!

Clearly an allosteric Tyk2 whilst being safe is overly selective and thus will.show very poor results in some Indications.

SDC1801 is Tyk2 Jak 1 inhibitor.

The Jak 1 has approx 4 to 5 fold selectivity over Jaks 2 and 3.

This will prove to have far greater success in areas in which Deucravacitinib have and will.flunk.

It is a very competitive field that we are involved in.

Tell me in your expert opinion how many Tyk2 Jak inhibitors have been approved for clinical.use and if not approved, the reasons for.

Whilst l.understand your concern for the Sareum performance it is in no way an indication of the future performance.

The SDC Co.pounds have value irrespective of the current SP.

RF have decimated the SP here, absolutely nothing to do with non existent failings in the Sareum pipeline.

Regards

Many will be aware of forward selling but an interesting link below.

https://www.sharesoc.org/blog/regulations-and-law/forward-selling-a-crime-against-shareholders/#:~:text=Forward%20selling%20occurs%20when%20a,prior%20to%20actually%20receiving%20them.